About Vor Biopharma
Vor Biopharma is a publicly listed company based in Cambridge (United States) founded in 2019 by Siddhartha Mukherjee. Developer of therapeutics to treat acute myeloid leukemia. Vor Biopharma has raised $152.12 million across 4 funding rounds from investors including RA Capital, Forbion and Venrock Capital Partners. The company has 159 employees. Its chief executive, as recorded, is Robert Yuen Lee Ang. Its website vorbio.com draws about 15 thousand monthly visits. Vor Biopharma offers products and services including Shielded Transplants and Genome Engineering Platform. Its focus areas include Life Sciences, Oncology, Drugs and Blood Cancer. Its competitors include Adicet Bio, Orca Bio and Ossium Health; 3 of its 3 listed competitors have raised funding.
Company details
Vor Biopharma was founded in 2019 and is headquartered in Cambridge, United States. Operations focus on the biotechnology sector, where engineered hematopoietic stem cells are utilized to create cancer therapeutics. The lead candidate, VOR33, is designed to target the CD33 protein in patients with acute myeloid leukemia. Additional efforts involve advancing treatments for hematologic malignancies through stem cell engineering.
- Headquarters Cambridge, United States
- Employees 159
- Founders Siddhartha Mukherjee
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website vorbio.com
- Social LinkedIn X Instagram
- Legal Name Vor Biopharma Inc.
- Net Profit-$695.98 M (USD)-495.29as on Dec 31, 2025
- EBITDA-$368.75 M (USD)-213.42as on Dec 31, 2025
- Total Equity Funding$152.12M (USD)
in 4 rounds
- Latest Funding Round$150M (USD), Post-IPO
Dec 2025
- InvestorsRA Capital
& 9 more
- Employee Count159
Products & Services of Vor Biopharma
Vor Biopharma offers a comprehensive portfolio of products and services, including Shielded Transplants and Genome Engineering Platform.
Engineered transplants for targeted blood cancer treatment
Platform for modifying cells to combat AML and blood cancers
Funding Insights of Vor Biopharma
Vor Biopharma has successfully raised a total of $152.12M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152.12M
- Total Rounds 4
- Last Round Post-IPO — $150M
- First Round $42M
(Feb 2019)
- Investors Count 10
All 4 funding rounds of Vor Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $150M | Post-IPO | – | – | |
| Jun 2025 | $175M | Post-IPO | – | – | |
| Jul 2020 | $110.12M | Series B | – | – | – |
| Feb 2019 | $42M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in Vor Biopharma
Vor Biopharma has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, Forbion and Venrock Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Venture capital investments in early stage B2B software and academic research startups. | osagepartners.com | |||
Healthcare investment firm focused on novel therapeutics development. | frazierls.com | |||
Private equity fund focused on the biotechnology sector | logoscapital.com | |||
Venture capital firm focused on tech sectors | venrock.com | |||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Investment firm providing advisory and partnership services in finance. | 2017 | caliganpartners.com | New York, United States | |
| nextbio.tcc.mode | ||||
| mingxincapital.tcc.mode |
Investor details for Vor Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vor Biopharma
17 people are tracked at Vor Biopharma (7 in leadership, 2 in board & advisors, 8 in team); the tracked headcount is 159.
| Name | Role | Group |
|---|---|---|
Siddhartha Mukherjee | Founder | Leadership |
Robert Yuen Lee Ang | CEO | Leadership |
Tania Philipp | VP and Head of People | Leadership |
Jeremy Sokolove | Chief Medical Officer | Leadership |
Leslie Drescher | Associate Director, Fp&a | Leadership |
Alexa S. | Executive Assistant & Head Of Administrative Operations | Leadership |
Dallan Murray | Evp, Chief Commercial Officer | Leadership |
Daniella Beckman | Director | Board & advisors |
Josh Resnick | Director | Board & advisors |
Edward Brauer | Medical Asset Strategy Lead | Team |
Mugdha Nikam | Senior Associate Scientist, Analytical Development | Team |
Erin A. Phelps | Senior Communications Manager | Team |
Gwayn Fernandes | Manufacturing Specialist II | Team |
Sherell Bacchas | SVP Finance And FPA | Team |
Yasmin Cuevas-Portorreal | Payroll, Accounts Payable, Equity Consultant | Team |
Matthew Dennen | Senior Manufacturing Manager | Team |
Yaashna Makhija | Associate Scientist II, Process and Analytical Development | Team |
Complete people profiles for Vor Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vor Biopharma
Vor Biopharma is a publicly listed company on the NASDAQ with ticker symbol VOR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Feb 2021
- Listed onNASDAQ: VOR
- Listed entityVor Biopharma Inc.
- Exchange sectorHealth technology
- ISINUS9290332074
- Share price$19.06 (-3.74% on the day) · 2026-10-13
- Market capitalisation$1.13B
- EPS (diluted, trailing year)$-83.39
- Volume (last session)949,440
Financials of Vor Biopharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$696.0M | -$368.8M | |
| 2024 | -$116.9M | -$117.7M | |
| 2023 | -$117.9M | -$122.5M | |
| 2022 | -$92.1M | -$84.5M | |
| 2021 | -$68.9M | -$64.6M |
Detailed financial statements for Vor Biopharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vor Biopharma
4 dated milestones of Vor Biopharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Vor Biopharma is founded.
- Funding First funding round of $42.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $150.0M.
Competitors of Vor Biopharma
Vor Biopharma has 3 listed competitors in our database, 3 of them funded. They include Adicet Bio, Orca Bio and Ossium Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adicetbio.com | 2014 | Menlo Park, United States | $51M | 86 | Immune cell therapies for cancer treatment are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $300M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| ossiumhealth.com | 2016 | San Francisco, United States | $125.41M | Ossium Health is focused on bioengineering for improved health. |
Detailed competitors of Vor Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vor Biopharma
The website of Vor Biopharma (vorbio.com) receives about 14.6K visits a month and ranks #1,790,867 among all websites worldwide, #2,430 in Biotechnology and Pharmaceuticals.
- Monthly visits14.6K
▲ 13.5% vs previous month
- Unique visitors5.7K
per month
- Global rank#1,790,867
among all websites
- Category rank#2,430
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.0
- Average visit40 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Vor Biopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| geneonline.com | 100% | 55.1K | #771,598 | View details | |
| biopharmadive.com | 100% | 680.7K | #208,628 | View details | |
| pharmaphorum.com | 100% | 128.2K | #451,885 | View details | |
| fiercebiotech.com | 80% | 858.3K | #81,022 | View details | |
cgtlive.com | cgtlive.com | 60% | #1,198,562 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Vor Biopharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Vor Biopharma (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vor Biopharma
Complete news archive for Vor Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vor Biopharma
Vor Biopharma was founded in 2019.
Vor Biopharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Robert Yuen Lee Ang is the CEO of Vor Biopharma, as recorded in our data.
Vor Biopharma is a funded company, having raised a total of $152.12M across 4 funding rounds to date. The company's 1st funding round was a Series A of $42M, raised on Feb 2019.
Vor Biopharma has 159 employees.
Vor Biopharma was founded in 2019 and is headquartered in Cambridge, United States. Operations focus on the biotechnology sector, where engineered hematopoietic stem cells are utilized to create cancer therapeutics. The lead candidate, VOR33, is designed to target the CD33 protein in patients with acute myeloid leukemia. Additional efforts involve advancing treatments for hematologic malignancies through stem cell engineering.
Vor Biopharma's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Vor Biopharma offers Shielded Transplants and Genome Engineering Platform.
Yes, Vor Biopharma is publicly traded on NASDAQ under the ticker symbol VOR.
Vor Biopharma has 10 investors. Key investors include RA Capital, Forbion, Venrock Capital Partners, Caligan Partners, and NEXTBio.
Vor Biopharma operates through Vor Biopharma.